We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




DNA Damage May Increase Risk of Breast Cancer

By Biotechdaily staff writers
Posted on 09 Aug 2006
Researchers have uncovered a pattern of DNA damage in breast connective tissues that could shed light on the early stages of breast cancer and perhaps serve as an early warning of an increased risk of cancer.

Breast cancer detection and therapy usually target epithelial cells, the primary site of breast cancers but in recent years new evidence has shown that genetic mutations that develop into cancer may initially occur in a deeper layer of the breast tissue called the stroma. More...
Genetic changes in this connective tissue has been reported to precede the malignant conversion of tumor cells, but the actual role of stromal cells in the early stages of breast cancer initiation and progression is not well understood.

Researchers from the Pacific Northwest Research Institute (PNRI, Seattle, WA, USA) and the U.S. National Institute of Standards and Technology (NIST, Boulder, CO, USA) explored the occurrence of damage to stromal DNA caused by free radicals and other oxidants. NIST researchers used a liquid chromatography/mass spectrometry with isotope dilution to identify specific DNA lesions, while the PNRI team used Fourier transform-infrared spectroscopy to reveal subtle conformational changes to DNA base and backbone structure. Alterations such as these can change or disrupt gene expression.

The teams identified a unique oxidation-induced lesion in the DNA of breast epithelium, myoepithelium, and stroma, and found that the highest concentrations of this lesion tended to occur in women 33-46 years old, a bracket that corresponds to a known rise in the incidence of breast cancer.

In a second paper, the team studied age-related concentrations of two similar mutagenic DNA lesions and again demonstrated that their occurrence is roughly commensurate with the age at which the incidence of female breast cancer rises.

"Collectively,” they observed, "the findings suggest that lesions measured in the DNA of the stroma, which is readily obtained, may prove to be convenient and sensitive biomarkers for assessing oxidative DNA damage and for signaling an increased breast cancer risk.



Related Links:
PRNI
NIST

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Chromogenic Culture System
InTray™ COLOREX™ ECC
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.